Literature DB >> 11739381

Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins.

Bansri Furia1, Longwen Deng, Kaili Wu, Shanese Baylor, Kylene Kehn, Hong Li, Robert Donnelly, Tim Coleman, Fatah Kashanchi.   

Abstract

Nuclear factor (NF)-kappaB transcription factors are involved in the control of a large number of normal cellular and organismal processes, such as immune and inflammatory responses, developmental processes, cellular growth, and apoptosis. Transcription of the human immunodeficiency virus type 1 (HIV-1) genome depends on the intracellular environment where the integrate viral DNA is regulated by a complex interplay among viral regulatory proteins, such as Tat, and host cellular transcription factors, such as NF-kappaB, interacting with the viral long terminal repeat region. CBP (CREB-binding protein) and p300, containing an intrinsic histone acetyltransferase (HAT) activity, have emerged as coactivators for various DNA-binding transcription factors. Here, we show that the p50 subunit as well as the p50/p65 of NF-kappaB, and not other factors such as SP1, TFIIB, polymerase II, TFIIA, or p65, can be acetylated by CBP/p300 HAT domain. Acetylation of p50 was completely dependent on the presence of both HAT domain and Tat proteins, implying that Tat influences the transcription machinery by aiding CBP/p300 to acquire new partners and increase its functional repertoire. Three lysines, Lys-431, Lys-440, and Lys-441 in p50 were all acetylated in vitro, and a sequence similarity among p50, p53, Tat, and activin receptor type I on these particular lysines was observed. All proteins have been shown to be acetylated by the CBP/p300 HAT domain. Acetylated p50 increases its DNA binding properties, as evident by streptavidin/biotin pull-down assays when using labeled NF-kappaB oligonucleotides. Increased DNA binding on HIV-1 long terminal repeat coincided with increases in the rate of transcription. Therefore, we propose that acetylation of the DNA binding domain of NF-kappaB aids in nuclear translocation and enhanced transcription and also suggest that the substrate specificity of CBP/p300 can be altered by small peptide molecules, such as HIV-encoded Tat.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739381     DOI: 10.1074/jbc.M107848200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

2.  Predicting transcription factor synergism.

Authors:  Sridhar Hannenhalli; Samuel Levy
Journal:  Nucleic Acids Res       Date:  2002-10-01       Impact factor: 16.971

3.  NF-κB inhibition delays DNA damage-induced senescence and aging in mice.

Authors:  Jeremy S Tilstra; Andria R Robinson; Jin Wang; Siobhán Q Gregg; Cheryl L Clauson; Daniel P Reay; Luigi A Nasto; Claudette M St Croix; Arvydas Usas; Nam Vo; Johnny Huard; Paula R Clemens; Donna B Stolz; Denis C Guttridge; Simon C Watkins; George A Garinis; Yinsheng Wang; Laura J Niedernhofer; Paul D Robbins
Journal:  J Clin Invest       Date:  2012-06-18       Impact factor: 14.808

4.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

5.  Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter.

Authors:  Sylvain Thierry; Vincent Marechal; Michelle Rosenzwajg; Michèle Sabbah; Gérard Redeuilh; Jean-Claude Nicolas; Joël Gozlan
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 6.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

7.  Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.

Authors:  Zong-Yang Li; Qing-Zhong Li; Lei Chen; Bao-Dong Chen; Bo Wang; Xie-Jun Zhang; Wei-Ping Li
Journal:  Neurochem Res       Date:  2016-09-08       Impact factor: 3.996

8.  Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer.

Authors:  Gouri Sankar Sen; Suchismita Mohanty; Dewan Md Sakib Hossain; Sankar Bhattacharyya; Shuvomoy Banerjee; Juni Chakraborty; Shilpi Saha; Pallab Ray; Pushpak Bhattacharjee; Debaprasad Mandal; Arindam Bhattacharya; Samit Chattopadhyay; Tanya Das; Gaurisankar Sa
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

9.  Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits.

Authors:  Ana M M Oliveira; Marcelo A Wood; Conor B McDonough; Ted Abel
Journal:  Learn Mem       Date:  2007-08-29       Impact factor: 2.460

10.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.